论文部分内容阅读
８１５例轻型缺血性卒中（ＭＩＳ）或ＴＩＡ病人随机分为阿斯匹林（ＡＳＡ）组（４１３例）与对照组（４０２例），随访１２～６０（平均２９．４）个月，结果发现：ＡＳＡ组卒中与死亡发生率（１５．３％）明显低于对照组（２４．４％）（Ｐ＜０．０１），ＡＳＡ组卒中与死亡危险性较对照组降低３７％［相对危险性（ＲＲ）为０．６３，９５％可信区间为０．４６～０．８６］；ＡＳＡ组卒中、血管性死亡及心肌梗塞发生率（２２．３％）显著低于对照组（３５．４％）（Ｐ＜０．００１），ＡＳＡ组卒中、血管性死亡及心肌梗塞危险性较对照组降低３６％（ＲＲ为０．６６，９５％可信区间为０．５０～０．８４）；ＡＳＡ组副作用发生率为１８．４％，严重副作用为２．７％。
815 patients with mild ischemic stroke (MIS) or TIA were randomly divided into aspirin (ASA) group (413 cases) and control group (402 cases), followed up for 12 to 60 (mean 29.4) months. Results Found that the incidence of stroke and death in ASA group was significantly lower than that in control group (15.3% vs 24.4%, P <0.01), and the risk of stroke and death in ASA group was 37% (RR 0.63, 95% confidence interval 0.46-0.86). The incidence of stroke, vascular death and myocardial infarction in ASA group (22.3%) was significantly lower than that in control group (35%). 4%) (P <0.001). The risk of stroke, vascular death, and myocardial infarction was decreased by 36% in the ASA group compared with the control group (RR 0.66, 95% CI 0.50-0.84) The incidence of side effects in ASA group was 18.4% and serious side effects were 2.7%.